Toward a global virus genomic surveillance network
The COVID-19 pandemic galvanized the field of virus genomic surveillance, demonstrating
its utility for public health. Now, we must harness the momentum that led to increased …
its utility for public health. Now, we must harness the momentum that led to increased …
[HTML][HTML] Mucosal vaccine delivery: A focus on the breakthrough of specific barriers
M Huang, M Zhang, H Zhu, X Du, J Wang - Acta Pharmaceutica Sinica B, 2022 - Elsevier
Mucosal vaccines can effectively induce an immune response at the mucosal site and form
the first line of defense against microbial invasion. The induced mucosal immunity includes …
the first line of defense against microbial invasion. The induced mucosal immunity includes …
[HTML][HTML] Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3
MT Yeh, M Smith, S Carlyle, JL Konopka-Anstadt… - Nature, 2023 - nature.com
Vaccination with Sabin, a live attenuated oral polio vaccine (OPV), results in robust intestinal
and humoral immunity and has been key to controlling poliomyelitis. As with any RNA virus …
and humoral immunity and has been key to controlling poliomyelitis. As with any RNA virus …
[HTML][HTML] Update on vaccine-derived poliovirus outbreaks—worldwide, July 2019–February 2020
MM Alleman - MMWR. Morbidity and mortality weekly report, 2020 - cdc.gov
Thirty-one ongoing and new cVDPV type 2 (cVDPV2) outbreaks were documented during
July 2019–February 2020; nine outbreaks spread internationally. New cVDPV2 outbreaks …
July 2019–February 2020; nine outbreaks spread internationally. New cVDPV2 outbreaks …
Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use
M Hill, AS Bandyopadhyay, AJ Pollard - The Lancet, 2022 - thelancet.com
Comment 714 www. thelancet. com Vol 400 September 3, 2022 risk of vaccine-associated
paralytic poliomyelitis caused by Sabin 2. 6 Although most countries eliminated Sabinlike …
paralytic poliomyelitis caused by Sabin 2. 6 Although most countries eliminated Sabinlike …
[HTML][HTML] Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and …
X Sáez-Llorens, AS Bandyopadhyay, C Gast… - The Lancet, 2021 - thelancet.com
Background Continued emergence and spread of circulating vaccine-derived type 2
polioviruses and vaccine-associated paralytic poliomyelitis from Sabin oral poliovirus …
polioviruses and vaccine-associated paralytic poliomyelitis from Sabin oral poliovirus …
Engineering antiviral vaccines
Despite the vital role of vaccines in fighting viral pathogens, effective vaccines are still
unavailable for many infectious diseases. The importance of vaccines cannot be overstated …
unavailable for many infectious diseases. The importance of vaccines cannot be overstated …
[HTML][HTML] Enabling accelerated vaccine roll-out for public health emergencies of international concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience
GR Macklin, C Peak, M Eisenhawer, F Kurji, O Mach… - Vaccine, 2023 - Elsevier
To address the evolving risk of circulating vaccine-derived poliovirus type 2 (cVDPV2),
Global Polio Eradication Initiative (GPEI) partners are working closely with countries to …
Global Polio Eradication Initiative (GPEI) partners are working closely with countries to …
Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised …
AL Wilkinson, K Zaman, M Hoque… - The Lancet Infectious …, 2023 - thelancet.com
Background Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
[HTML][HTML] Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence …
SB Kennedy, GR Macklin, GM Ross… - The Lancet Global …, 2023 - Elsevier
Background Novel oral poliovirus vaccine type 2 (nOPV2) was administered in Liberia in
response to an outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2) in 2021 …
response to an outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2) in 2021 …